Recro Pharma, Inc. (NASDAQ:REPH) Files An 8-K Other Events
Item 8.01 Other Events.

On October5, 2017, Recro Pharma, Inc. (the “Company”) issued a press release announcing the PDUFA Date for IV Meloxicam 30mg. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 8.01 Financial Statements and Exhibits.

(d)Exhibits

The exhibit filed as part of this Current Report on Form 8-K is set forth on the Exhibit Index, which Exhibit Index is incorporated herein by reference.

EXHIBIT INDEX

Recro Pharma, Inc. Exhibit
EX-99.1 2 d470404dex991.htm EX-99.1 EX-99.1 Exhibit 99.1   Recro Pharma Announces PDUFA Date for IV Meloxicam 30mg PDUFA Date Set For May 26,…
To view the full exhibit click here

About Recro Pharma, Inc. (NASDAQ:REPH)

Recro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.